Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT06164327 Recruiting - Clinical trials for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open Phase Ib clinical study to evaluate the safety,efficacy and pharmacokinetics of BEBT-908 combined with Rituximab (R) or combined with Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) or combined with Rituximab-Ifosfamide-Carboplatin-Etoposide (R-ICE) in the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

NCT ID: NCT06161896 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Characterization and Clinical Impact of the Gut Microbiota in Lymphoma

Start date: May 6, 2024
Phase:
Study type: Observational

The study is a prospective observational single-center cohort study which compare the gut microbiome of newly diagnosed Diffuse Large B-cell Lymphoma patients with the gut microbiome of healthy controls. Furthermore the impact of lymphoma treatment, immune phenotypes, cytokine profiles, metabolomics, inflammation, driver mutations, comorbidity, body composition and lifestyle on the microbiome is also investigated

NCT ID: NCT06160362 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Start date: October 31, 2023
Phase: N/A
Study type: Interventional

This is a study for patients who have been previously treated for NHL. The purpose of this study is to determine the safety and feasibility of double-target CART-19 and 20 cells to the patients with relapsed and refractory CD19+/CD20+ NHL.

NCT ID: NCT06158399 Recruiting - Clinical trials for DLBCL - Diffuse Large B Cell Lymphoma

AZA Combined With RCHOP in P53-mutated DLBCL.

Start date: November 22, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma

NCT ID: NCT06156774 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Start date: April 18, 2024
Phase:
Study type: Observational

This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.

NCT ID: NCT06151080 Recruiting - Follicular Lymphoma Clinical Trials

Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

Start date: November 22, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and adverse effects of lenalidomide combined with G-CHOP(LO-CHOP) in the treatment of newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL).

NCT ID: NCT06149169 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Start date: August 17, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.

NCT ID: NCT06142188 Not yet recruiting - Follicular Lymphoma Clinical Trials

Relmacabtagene Autoleucel in Hematologic Malignancies

Start date: December 28, 2023
Phase:
Study type: Observational

To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world

NCT ID: NCT06142175 Recruiting - Clinical trials for Large B-cell Lymphoma

Relmacabtagene Autoleucel in Patients With LBCL

Start date: December 28, 2022
Phase:
Study type: Observational

To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world

NCT ID: NCT06141772 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy

LYMPHO-CLEAR
Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the kinetics of circulating tumor DNA (ctDNA) in the hours following initial administration of immuno-chemotherapy to patients with diffuse large B cell lymphoma (DLBCL). Modelizing the short-term kinetics of ctDNA would help to determine the optimal time-point for ctDNA follow-up. The investigators hypothesize that the greater ctDNA release at this time-point compared to baseline might lead lead to the detection of novel variants compared to baseline.